triamcinolone suprachoroidal (Rx)

Brand and Other Names:Xipere
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic suspension for suprachoroidal injection

  • 40mg/mL single-dose vial

Macular Edema

Indicated for macular edema associated with uveitis

4 mg as a single suprachoroidal injection for treatment of 1 eye

Safety and efficacy not established

Next:

Adverse Effects

>10%

Increased intraocular pressure (IOP), nonacute (14%)

Eye pain, nonacute (12%)

1-10%

Cataract (7%)

Increased IOP, acute (6%)

Vitreous detachment (5%)

Headache (5%)

Injection site pain (4%)

Conjunctival hemorrhage (4%)

Reduced visual acuity (4%)

Dry eye (3%)

Eye pain, acute (3%)

Photophobia (3%)

Vitreous floaters (3%)

Uveitis (2%)

Conjunctival hyperemia (2%)

Punctate keratitis (2%)

Conjunctival edema (2%)

Meibomianitis (2%)

Anterior capsule contraction (2%)

Chalazion (2%)

Eye irritation (2%)

Eye pruritus (2%)

Eyelid ptosis (2%)

Photopsia (2%)

Vision blurred (2%)

Previous
Next:

Warnings

Contraindications

Hypersensitivity to triamcinolone and other product components

Cautions

Corticosteroid-related effects

  • May produce cataracts, increased IOP, and glaucoma
  • May enhance establishment of secondary ocular infections due to bacteria, fungi, or viruses
  • Caution with history of ocular herpes simplex
  • Do not use with active ocular herpes simplex

Altered endocrine function

  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing syndrome, and hyperglycemia can occur, particularly with long-term use
  • Corticosteroids can produce reversible HPA axis suppression with potential for glucocorticosteroid insufficiency following withdrawal; minimize by gradual dose reduction
  • This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, reinstitute hormone therapy
  • Corticosteroid clearance decreased with hypothyroid and increased with hyperthyroid; changes in thyroid status may necessitate dose adjustment
Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no adequate and well-controlled studies in pregnant women to inform drug-associated risks

Systemic exposure is negligible following suprachoroidal injection

Animal studies

  • Topical ocular administration of corticosteroids has been shown to produce teratogenicity at clinically relevant doses

Lactation

Unknown if ocular administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Corticosteroid; suppresses inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells

Absorption

Among 19 patients, 18 of 19 had serum concentrations below the lower limit of quantitation

Previous
Next:

Administration

Suprachoroidal Injection Preparation

Suprachoroidal injection procedure is performed under controlled aseptic conditions, including use of sterile gloves, sterile drape, sterile eyelid speculum (or equivalent), and sterile cotton swab

Apply adequate anesthesia and broad-spectrum microbicide to periocular skin, eyelid, and ocular surface before the injection

See prescribing information for complete preparation instructions and diagrams

Suprachoroidal Injection

See prescribing information for complete preparation instructions and diagrams

Monitor intraocular pressure immediately after injection

Storage

Store at 15-25ºC (59-77ºF)

Store in original carton to protect from light

Do not freeze

Discard unused portion

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.